Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

Chungnam National University Hospital150 enrolled

Overview

Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Patients described above randomly assigned to drug tapering group and drug maintaining group. Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group. Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

150

Conditions

Heart Failure Ejection Fraction Recovery of Function

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * initial echocardiogram ejection fraction less than 40% * follow up echocardiogram ejection fraction over 50% and LVEDD index normal range * NTprobnp criteria 1. eGFR ≥60 ; less 440 2. eGFR 45-59: less 980 3. eGFR 30-44; less 1220 4. eGFR \< 30 : less 5300 5. in HD; no criteria for NTproBNP * on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor) Exclusion Criteria: 1. under age 18 year 2. uncontrolled BP ( over 150/90) 3. coronary revascularization within 6 months 4. significant valve disease 5. arrhythmia requiring rate control 6. CKD with albuminuria ( over 30mg/g) 7. Pregnancy

Locations (2)

Jeonbuk national university hospital

Jeonju, Jeollabuk-do, South Korea

RECRUITING

Chungnam national university hospital

Daejeon, Republic of Korea, South Korea